Neuland Laboratories Limited (NEULANDLAB) fair value: what the stock is really worth
We calculate from audited financials what Neuland Laboratories Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
Compare price with fair valuebelow fair value = cheap, above = expensive
Check the quality50 and up solid, 75 and up strong
Watch it or check another stockalert when fair value or trend changes
Healthcare · IN · Market cap ₹298B (≈ $3.1B) · ISIN INE794A01010
At a glance
NLNeuland Laboratories LimitedNEULANDLAB · NSE
Price₹23,195
Fair Value₹5,987
Upside−74.2%
Quality53/100
A solid business, but trading 287% above our fair value of ₹5,987.
As of Aug 23, 2026, the fair value of Neuland Laboratories Limited is ₹5,987 per share against a price of ₹23,195, so the fair value sits 74% below the price. A model estimate from reported figures, not an analyst target.
!Expensive Growth (revenue 5y +17.1 %/yr)
!Thin margins · 2.3% net margin
!Low debt · negative free cash flow
✓Ranks above peers (8/13)
!Moderate moat 62/100
!Weak on dividend: 1 out of 100
Evidence: HighRange ₹4,191 to ₹7,802
Fair value as of: Aug 23, 2026
From 17 valuation models · updated 18 days ago
Share price +4.4% over the past month.
This is the short version. In the app for Neuland Laboratories Limited:
Watch Neuland Laboratories Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceable See the method →
What matters now
The price sits above even our optimistic bull case (₹7,802). The favourable scenario is already priced in.
Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
A fairly wide model range (₹4,191 to ₹7,802) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 23, 2026.
How to read this chart
60‑month range ₹963.46 – ₹23,995 · fair‑value band ₹4,191 – ₹7,802 · the ₹23,195 price screens above the ₹5,987 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 23, 2026.
Neuland Laboratories Limited (NEULANDLAB) currently trades at ₹23,195, while our model-based Fair Value estimate is ₹5,987, implying the stock looks roughly 287.4% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ₹5,987 per share, and 0 of the 17 models we run sit above the ₹23,195 price. Bear case: the Asset-Based group reads lowest at ₹978.88, and 17 of the 17 models stay below the price. Evidence for this calculation is high.
Revenue grew 136.4% year over year. It earns a return on equity of 15.9%. The balance sheet holds a net cash position of ₹537M. The stock trades on a trailing P/E of 81.8. Fundamentals as of Aug 23, 2026
Scenario range: ₹4,191 (bear) to ₹7,802 (bull), the price of ₹23,195 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades near its 52-week high and 102% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −74%, NEULANDLAB screens richer than that median.
Fair Value models
Based on fiscal year 2026 figures (about 5 months old). Earnings retained since then (₹126.68 per share) are deliberately not added.
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (₹206.43 to ₹9,976). Read the values as a conservative anchor, not as a price target.
ModelBear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence
Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
P/E ratio81.8
P/S ratio14.7P/E × margin
EPS (TTM)₹283.67price ÷ EPS = P/E 81.8
Dividend yield0.1%payout 5.2%
Net margin18.0%FY2026
Return on equity15.9%TTM
More key figures
Profitability
Return on assets (EBIT)14.5%avg 5y
Operating margin36.4%TTM
Growth
Revenue growth (YoY)+136%3y avg +20.3%
EPS growth (YoY)+664%
Balance sheet & cash flow
Free cash flow−₹589MFY2026
Net cash₹537MFY2026
Figures from reported company fundamentals · as of Aug 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Overall quality53/100
Of which business quality 54
· Market factors (momentum, volatility) 92
Profitability62
Margins and returns on capital today
Quality Growth56
Are margins and returns improving?
Cashflow24
Earnings quality: real cash, not paper profit
Fin. Strength87
Balance sheet, leverage, solvency risk
Investment1
Disciplined investing over empire-building
Low Volatility74
Calm price path (market factor)
Momentum99
Price trend over the last 3–12 months (market factor)
52W Momentum100
Distance to the 52-week high (market factor)
Net Issuance82
Buybacks instead of dilution
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Neuland Laboratories Limited reported revenue of ₹20.2B in FY2026 versus ₹9.2B in FY2022, a compound +21.7%/yr. Reported net income was ₹3.6B in FY2026, compounding +54.5%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Growth Quality 57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2026)
₹20.2B
Latest YoY
+41.0%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+20.3%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+17.1%
Avg. revenue growth/yr (20Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.4%
Value creation/yr (5Y, in INR) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+41.8%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+41.7%
Dividend yield0.1%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y 41.7% vs 10Y 24.9%, picking up
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11.9% (2021) → 23.9% (2026) · rising
Worst earnings drop148% (2010) (loss year, drop beyond 100%) · in INR
Revenue+21.7%/yr
FY22₹9.2B
FY23₹11.6B
FY24₹15.2B
FY25₹14.3B
FY26₹20.2B
Net income+54.5%/yr
FY22₹638M
FY23₹1.6B
FY24₹3.0B
FY25₹2.6B
FY26₹3.6B
Character of growth · EPS growth decomposed (2015-2026)+25.3 % p.a.
Revenue per share+10.2 %
of which total revenue +13.9 % · buybacks/dilution −3.3 %
EBIT margin+6.4 %
Tax rate+1.2 %
Residual (interest, one-offs)+5.6 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
This stockSector peers
VALUE0· sector 4
FUTURE100· sector 22
PAST64· sector 25
HEALTH96· sector 97
DIVIDEND1· sector 29
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 23, 2026).
Is Neuland Laboratories Limited (NEULANDLAB) overvalued or undervalued?
As of Aug 23, 2026, our model estimates a fair value of ₹5,987 versus a price of ₹23,195, about −74% upside (overvalued).
What is the fair value of NEULANDLAB?
Our model-based fair value for Neuland Laboratories Limited is ₹5,987 (as of Aug 23, 2026), built from audited fundamentals. The current price: ₹23,195.
What is the quality score of NEULANDLAB?
Neuland Laboratories Limited has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neuland Laboratories Limited (NEULANDLAB)?
Our model-based price target is the fair value of ₹5,987 (as of Aug 23, 2026) from 17 valuation models. Cautious scenario ₹4,191, optimistic scenario ₹7,802. It is a calculation from audited fundamentals, not an analyst target.
What is the Neuland Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹5,987, about −74% upside versus a price of ₹23,195 (overvalued). Cautious scenario ₹4,191, optimistic scenario ₹7,802. The calculation is refreshed regularly with new filings.
What is the net profit margin of NEULANDLAB?
The net profit margin of Neuland Laboratories Limited is about 2.3%, meaning it keeps roughly 2.3% of revenue as net income. Based on the latest reported figures.
Does Neuland Laboratories Limited pay a dividend?
Neuland Laboratories Limited currently shows a dividend yield of about 0.06% relative to its recent price (as of Aug 23, 2026).
What is the intrinsic value of Neuland Laboratories Limited (NEULANDLAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neuland Laboratories Limited it is ₹5,987 per share (as of Aug 23, 2026), against a price of ₹23,195. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Neuland Laboratories Limited stock overvalued or undervalued in 2026?
As of Aug 23, 2026, NEULANDLAB trades above its calculated fair value: price ₹23,195, fair value ₹5,987, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NEULANDLAB?
No. The price is what the market pays today (₹23,195); the fair value is what the company's own numbers justify (₹5,987). For Neuland Laboratories Limited the two are ₹17,208 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neuland Laboratories Limited worth?
The market values Neuland Laboratories Limited at about ₹298B (market capitalisation, as of Aug 23, 2026). Per share that is ₹23,195; our models calculate a fair value of ₹5,987 per share.
What do the bullish and bearish scenarios say about NEULANDLAB?
Our models span a range for Neuland Laboratories Limited: cautious scenario ₹4,191, base ₹5,987, optimistic ₹7,802 per share (as of Aug 23, 2026, price ₹23,195). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NEULANDLAB?
Neuland Laboratories Limited trades at a price-to-earnings ratio of 81.8 (as of Aug 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹5,987 is built from several models across several years. Other multiples: P/B 0.1, P/S 0.4, EV/EBITDA 1.2.
How solid is the balance sheet of Neuland Laboratories Limited (NEULANDLAB)?
Balance-sheet figures for Neuland Laboratories Limited (as of Aug 23, 2026): return on equity 15.9%, debt of 0.09 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is NEULANDLAB from its 52-week high?
Neuland Laboratories Limited trades at ₹23,195, about 17% below its 52-week high of ₹19,747 and 102% above the low of ₹11,500 (as of Aug 23, 2026). Distance from the high says nothing about value: that is what the fair value of ₹5,987 is for.
Which stocks are comparable to Neuland Laboratories Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neuland Laboratories Limited stock attractive at the current price?
The data as of Aug 23, 2026: price ₹23,195, calculated fair value ₹5,987 (−74%), Quality Score 53/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NEULANDLAB calculated?
We run Neuland Laboratories Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹5,987, with the spread shown as a cautious and an optimistic scenario.
Free · no account needed
Watch Neuland Laboratories Limited in the live analysis
One click puts Neuland Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
